News | Prostate Cancer | April 11, 2022

Innovative technology performs automatic segmentation and lesion detection in prostate MRI scans to assist in PI-RADS scoring for prostate cancer management

RSIP Vision, an experienced leader in driving innovation for medical imaging through advanced artificial intelligence (AI) and computer vision solutions, announced a new tool for prostate MRI analysis.

April 11, 2022 — RSIP Vision, an experienced leader in driving innovation for medical imaging through advanced artificial intelligence (AI) and computer vision solutions, announced a new tool for prostate MRI analysis. The tool performs segmentation of the prostate, its sub-sections, and lesions. It analyzes the lesions’ intensity, restriction, size, and shape, and provides a baseline for Prostate Imaging–Reporting and Data System (PI-RADS) score. This information is reported to the radiologist for consideration, reducing examination time and lowering misdiagnosis rate. This new vendor-neutral technology will be available to third-party MRI manufacturers and viewer solutions, allowing a more accurate and efficient way to report prostate MRI examination.

“MRI is an advanced imaging tool, specifically for soft tissue like the prostate gland, with potential for improvement using AI,” said Ron Soferman, CEO at RSIP Vision. “Deep learning (DL) algorithms can be developed for accurate segmentation of the prostate, the transition zone (TZ), the peripheral zone (PZ), and the suspicious lesions. The system can automatically detect and calculate the lesions’ dimensions, volume, intensity, restriction, and edge smoothness in all the different scan parameters. Additionally, this tool can compare current and previous scans and highlight the differences, providing additional feedback for the radiologist prior to scoring.”

The PI-RADS scoring method was developed to allow uniform scale for prostate cancer assessment. It consists of descriptive parameters for the lesion shape, location, intensity, and restriction, each of which corresponds to a different score representing suspicious features for prostatic cancer. Currently, it is performed manually and is a time-consuming task for radiologists, with a high rate of inter-observer variability. RSIP Vision’s new PI-RADS assistant provides objective analysis of the prostate MRI scan, with measurable statistics which can be used to improve scoring accuracy. Also, it is common to perform follow-up scans in patients diagnosed with prostatic cancer. The PI-RADS assistant compares lesions from previous scans and presents the differences to the radiologist, providing a map of the lesion growth, withering, or stability.

“Prostate MRI scans are very common, and their rate increases with increasing life expectancy,” said Dr. Rabeeh Fares, Senior radiologist at Sourasky Medical Center, Tel Aviv, Israel. “Reviewing these scans accounts for a large portion of the radiologist’s workload. The PI-RADS assistant will significantly reduce examination time, improve scoring accuracy and precision, and ultimately lead to better clinical outcomes.”

For more information: www.rsipvision.com

Related prostate MRI content:

MRI-guided Radiotherapy Appears to Lead to Fewer Side Effects from Treatment for Prostate Cancer

Mount Sinai Health System Launches First-Ever Mobile Prostate Cancer Screening Unit in New York City

Genetics Predicts Toxic Side Effects to Prostate Cancer Radiotherapy

3-D Imaging Method May Help Doctors Better Determine Prostate Cancer Aggressiveness

Black Patients 24% Less Likely than White Patients to Have a Prostate MRI After Receiving an Elevated PSA Score


Related Content

News | ASTRO

Sept. 29, 2026 — The American Society for Radiation Oncology (ASTRO) has named Siemens Healthineers the inaugural ...

Time September 29, 2026
arrow
News | Proton Therapy

Sept. 28, 2026 — Penn Medicine and Ion Beam Applications (IBA) have formed Noventra Oncology Alliance, a new joint ...

Time September 28, 2026
arrow
News | Digital Pathology

Sept. 24, 2026 — Leica Biosystems,has added two Paige digital pathology AI-enabled products from Tempus to its Aperio AI ...

Time September 25, 2026
arrow
News | ASTRO

Sept. 22, 2026 — Leading experts in radiation therapy from the Abramson Cancer Center (ACC) of the University of ...

Time September 24, 2026
arrow
News | RSNA

Sept. 22, 2026 — The Radiological Society of North America (RSNA) is now offering a certificate program that equips ...

Time September 24, 2026
arrow
News | Molecular Imaging

Sept. 22, 2026 — Blue Earth Diagnostics, a part of the Bracco Group, has announced new research examining how precision ...

Time September 23, 2026
arrow
News | ASTRO

Sept.16, 2026 — For appropriately selected patients with muscle-invasive bladder cancer, preserving the bladder can be a ...

Time September 17, 2026
arrow
News | Ultrasound Imaging

Sept. 16, 2026 — Ultrasound AI, Inc., a developer of artificial intelligence for medical imaging with a focus on ...

Time September 17, 2026
arrow
News | CT Angiography (CTA)

Sept. 15, 2026 — A new study published in the Journal of the American College of Radiology (JACR) found that an ...

Time September 15, 2026
arrow
News | Radiology Imaging

Sept. 1, 2026 — Leo Cancer Care and GE HealthCare have announced that the two companies intend to work together on GE ...

Time September 11, 2026
arrow
Subscribe Now